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Abstract
Background: Mutations in LRRK2 encoding leucine-rich repeat kinase 2 are thus far the most
frequent genetic cause associated with autosomal dominant and idiopathic Parkinson's disease
(PD). To examine whether LRRK2 is directly associated with neuropathology of PD and other
related disorders, we analyzed LRRK2 in brains of patients affected by PD and dementia with Lewy
bodies (DLB) using highly specific antibodies to LRRK2.
Results: We demonstrated that anti-LRRK2 antibodies strongly labelled brainstem and cortical
Lewy bodies, the pathological hallmarks of PD and DLB, respectively. In addition, anti-LRRK2 also
labelled brain vasculature, axons, and neuronal cell bodies. Interestingly, the immunocytochemical
profile of LRRK2 varied with different antibodies depending upon specific antigenic sites along the
LRRK2 protein. All anti-LRRK2 antibodies tested that were raised against various regions of
LRRK2, were found to be immunoreactive to recombinant LRRK2 on Western blots. However,
only the antibodies raised against the N-terminal and C-terminal regions of LRRK2, but not the
regions containing folded protein domains, were positive in immunolabeling of Lewy bodies,
suggesting a differential exposure of specific antigenic sites of LRRK2 on tissue sections.
Conclusion: We conclude that LRRK2 is a component of Lewy bodies in both PD and DLB, and
therefore plays an important role in the Lewy body formation and disease pathogenesis.
Information on the cellular localization of LRRK2 under normal and pathological conditions will
deepen our understanding of its functions and molecular pathways relevant to the progression of
PD and related disorders.
Background
Parkinson's disease (PD) is the most common neurode-
generative disorder of the extrapyramidal system, affect-
ing up to 3% of individuals aged 65 years and older and
over 1 million people in North America [1,2]. The disease
is characterized clinically by resting tremor, rigidity,
bradykinesia, and postural instability and pharmacologi-
cally by response to l-dopa treatment. Neuropathologi-
cally, it is associated with selective loss of dopaminergic
neurons and the presence of intracytoplasmic proteina-
ceous inclusions, known as Lewy bodies (LBs), in the sub-
stantia nigra [1]. The etiology and pathogenesis of PD
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genetic basis for PD. Mutations in genes encoding parkin,
PTEN-induced putative kinase 1, and DJ-1 are segregated
with autosomal recessive, early-onset familial PD,
whereas those in genes encoding α-synuclein and leucine-
rich repeat kinase 2 (LRRK2) are linked to autosomal
dominant PD [3-5]. Of these five genes, only LRRK2
mutations have been shown to be both a common cause
and a risk factor for familial PD and sporadic PD, respec-
tively. LRRK2 mutations accounted for up to 6–40% of
familial PD cases depending on the ethnic populations
studied, and up to 2% of community-base sporadic PD
cases [6-11].
The clinical and pathological features associated with the
LRRK2 mutations are in most cases consistent with those
of late-onset PD but may vary depending on the type of
pathogenic mutations. It has been reported that patients
carrying the most common G2019S mutation present a
disease phenotype that is indistinguishable from idio-
pathic PD, which is characterized by classical Lewy body
pathology [12-14]. Instead, patients carrying the less com-
mon R1441C and Y1699C mutations may have a more
variable disease presentation that can include PD and
other clinical parkinsonism such as dementia with Lewy
bodies (DLB) and progressive supranuclear palsy [4].
These apparently pleomorphic pathologies may reflect the
effect of specific pathogenic substitutions on the structure
and function of LRRK2.
The neuropathological hallmark of PD is the presence of
spherical LBs in affected brainstem. LB inclusions are also
a prominent pathological feature of DLB, but are of more
diffused nature and are found in cortical regions [15].
Among proteins genetically associated with PD, α-synu-
clein and parkin have been previously shown to be com-
ponents of LBs in both PD and DLB [16-18]. Both α-
synuclein and parkin are known to be phosphoproteins
[19-21] and hence are potentially regulated by LRRK2
serving as a functional kinase [22,23]. It is therefore of
particular interest to determine whether LRRK2 also local-
izes to LBs. Given that LRRK2 is such a large protein with
2527 amino acids and multiple protein domains, we per-
formed a detailed analysis of LRRK2 localization by using
a battery of antibodies against different regions spanning
the entire protein to address this important issue. Here we
provide strong evidence that LRRK2 is localized, both in
situ and following isolation, to LBs in both PD and DLB.
Results
Protein biochemistry
LRRK2 is predicted to be a large protein of 2527 amino
acids with a complex composition including five consecu-
tive domains; leucine-rich repeats (LRRs), Ras of complex
protein (ROC), C-terminal of ROC (COR), mitogen-acti-
vated protein kinase kinase kinase (MAPKKK), and WD40
repeats [24]. To determine the expression and localization
of LRRK2 in brain, four affinity-purified antibodies
against LRRK2 were used for Western blotting and immu-
nocytochemistry. These antibodies were raised against dif-
ferent regions of LRRK2 that span the entire protein (see
Materials and Methods for details). The epitopes for Ab1
and Ab4 are located at the N-terminal and C-terminal to
(and hence outside) the core protein domains of LRRK2,
respectively, while those for Ab2 and Ab3 are located
within the domains of LRRs and COR/MAPKKK, respec-
tively. To characterize the immunoreactivity of these anti-
bodies to LRRK2, we expressed human LRRK2 in
HEK293T and M17 cells by transient transfection with a
mammalian expression vector pCMV6-XL4/LRRK2. On
Western blots, all four antibodies (Ab1, Ab2, Ab3 and
Ab4) readily detected a prominent LRRK2 band migrated
at about 280 kDa, the size expected for the full-length
LRRK2, in lysates of transfected cells but not in non-trans-
fected cells (Figure 1A). Thus, all four antibodies are
highly specific for LRRK2 overexpressed in cultured cells.
Both non-neuronal (HEK293T) and neuronal (M17) cell
lines produced high levels of LRRK2 following transient
transfection with its cDNA construct. The endogenous
LRRK2 in non-transfected cells were not detected at the
total protein level loaded (10 μg of lysates). Taken
together, our results indicate that under denaturing condi-
tions of SDS-PAGE, the epitopes of LRRK2 in different
sites are fully exposed and can be readily recognized by
corresponding antibodies on Western blots.
We have attempted to use these anti-LRRK2 antibodies to
detect brain LRRK2 in subjects without neurological dis-
eases and those with sporadic PD. Results from anti-
LRRK2 Ab4 was presented here but similar data were
obtained with other antibodies. As an additional control
for the specificity of anti-LRRK2 Ab4, we performed the
antigen absorption experiment in which the antibody was
incubated with its corresponding peptide antigen prior to
Western blotting. As shown in Figure 1B, the immunore-
activity to LRRK2 by anti-LRRK2 Ab4 was completely
blocked following the absorption with its antigen, con-
firming that the antibody is highly specific for LRRK2.
Brain LRRK2 was expressed at low levels but was detecta-
ble by using anti-LRRK2 Ab4 when 100 μg of total protein
of brain homogenates were used. The LRRK2 bands from
brain samples had same gel migration at 280 kDa as that
from transfected cells, with little evidence of degradation
or autolysis. Endogenous LRRK2 in brain homogenates
from two control subjects and two PD patients was specif-
ically recognized by anti-LRRK2Ab4 (Figure 1B). Overall
intensity of the LRRK2 band was stronger in these PD
samples as compared to the controls. In summary, LRRK2
from cultured cells and brain tissue can be specificallyPage 2 of 9
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against a broad range of epitopes along the protein.
Immunocytochemistry-PD
All four antibodies were used to immunostain brainstem
sections from six cases of PD and age-matched controls.
Most notable was the finding that in all cases of PD exam-
ined, LBs in the brainstem were intensely labelled with
Ab1 and Ab4 recognizing LRRK2900–1000 that is immedi-
ately N-terminal to the first LRRs domain and LRRK22500–
2527 at the extreme C-terminus, respectively (Figure 2A and
2D). Both rim and core of brainstem LBs were labelled by
Ab1 and Ab4, with a similar pattern to that seen with an
antibody to α-synuclein, a well-established component of
Lewy bodies [16,17]. Indeed, LBs stained for LRRK2 and
α-synuclein on adjacent sections revealed significant over-
lap (data not shown). In contrast, Ab2 and Ab3 recogniz-
ing the internal LRRK21246–1265 and LRRK21838–2133,
respectively, did not recognize LBs in any of the PD cases
studied (Figure 2B and 2C), as was similarly found for
Ab2 in an earlier report [25]. Therefore, unlike that on
Western blots, only the antibodies to the LRRK2 regions
outside, but not within, the five core protein domains are
able to immunostain LRRK2 localized in LBs on tissue sec-
tions. Our findings suggest that the epitopes within the
folded protein domains are inaccessible under the condi-
tions used for routine immunohistochemistry.
LRRK2 was also found to be prominent in the vasculature
throughout the brainstem and cortical regions. This pat-
tern was also found in non-diseased tissue. Interestingly,
antibodies to LRRK21838–2133 (Ab3, Figure 2G), as well as
LRRK2900–1000 (Ab1, Figure 2E) and LRRK22500–2527 (Ab4,
Figure 2H) labelled the vasculature, whereas the antibody
to LRRK21246–1265 (Ab2, Figure 2F) was still negative for
vessel staining. In addition, neuronal cell bodies and
axons were strongly labelled by Ab4 (Figure 2H) in all
cases of PD but much less intense in control cases (Figure
2L). The same pattern was also found in both PD and aged
control cases with Ab1 (Figure 2E and 2I). However, no
neuronal stain was seen with either Ab2 or Ab3 (Figure 2J
and 2K). In contrast, small neuritic processes positive with
anti-synuclein, were rarely labelled by any of the anti-
LRRK2 antibodies (not shown). We confirmed that the
immunostaining of LBs and other structures positive for
LRRK2 was highly specific as it was mostly abolished fol-
lowing absorption of the primary antibodies with the cor-
responding peptide antigens of LRRK2 (Figure 3). Taken
together, we conclude that LRRK2 within the blood vessel
and neuronal structures (neuronal cell bodies and axons)
shows differential regional exposure of antigenic sites as
demonstrated by its distinct accessibility to different anti-
bodies.
Immunocytochemistry-DLB
In tissue sections from six cases of DLB, cortical LBs were
also labelled by the Ab4 and Ab1 antibodies to C- and N-
terminal LRRK22500–2527 and LRRK2900–1000 regions,
respectively (Figure 4A and 4B), but not by Ab2 and Ab3
to the internal regions of LRRK21246–1265 and LRRK21838–
2133. These findings are very consistent with that for brain-
stem LBs of PD, confirming the notion that LBs from PD
and DLB may have similar compositions despite different
morphology and location. While the α-synuclein anti-
body stained cortical LBs exclusively, anti-LRRK2 Ab4 rec-
ognizes not only cortical LBs, but also neuronal cytoplasm
(Figure 4C) more intensely than age-matched controls
(Figure 4D), and vessel walls (Figure 4H). Ab1 also
strongly labelled neuronal cytoplasm in these cases, but
displaying a more granular pattern (inset in Figure 4C).
Purified cortical LBs, biochemically isolated from DLB
brains [15], were positive for staining by both anti-α-
synuclein (Figure 4F) and anti-LRRK2 Ab4 (Figure 4E),
whereas omitting the primary antibody revealed no labe-
ling of the purified cortical LBs (Figure 4G). Taken
together, our results strongly indicate that LRRK2 is local-
ized to LBs both in situ and following isolation, and is a
specific biochemical marker for PD and DLB.
Western blotting of LRRK2Figure 1
Western blotting of LRRK2. A. Recombinant LRRK2 
(arrowhead) from transfected (+) HEK 293T and M17 cells 
was specifically recognized by all four LRRK2 antibodies 
(Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not 
recognized in non-transfected cells (-). B. Recombinant 
LRRK2 (arrowhead) from transfected M17 cells is detected 
by anti-LRRK2 Ab4 (lane 1), but not after absorption of the 
antibody with its peptide antigen (lane 2). Brain LRRK2 was 
recognized by anti-LRRK2 Ab4 in two controls (lanes 3 and 
4) and two PD cases (lanes 5 and 6). Cell lysates (10 μg pro-
tein) and brain homogenates (100 μg protein) were prepared 
and loaded on 6% SDS-PAGE gels for Western blot analysis 
using anti-LRRK2 antibodies Ab1–Ab4 in (A) and Ab4 in (B).Page 3 of 9
(page number not for citation purposes)
Molecular Neurodegeneration 2006, 1:17 http://www.molecularneurodegeneration.com/content/1/1/17
Page 4 of 9
(page number not for citation purposes)
Immunocytochemistry of LRRK2 in PDFigure 2
Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions 
shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) and age-matched controls 
(I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) and Ab4 against 
LRRK22500–2527(D). Both rim (A and D) and core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any 
case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are 
located within the folded domains. The cell bodies of both pigmented and no-pigmented neurons (arrows) as well as axons 
(arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E and Ab4, H). In con-
trast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large and small vessels was consistently 
found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, and H) and strikingly the vessels are the only struc-
ture immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G and K). Ab2 to LRRK21246–1265 did not recog-
nize LBs, cell bodies or vessels in any case (B, F, and J). Scale bars: A-D and inset = 10 μm; E-L = 100 μm.
Molecular Neurodegeneration 2006, 1:17 http://www.molecularneurodegeneration.com/content/1/1/17Discussion
To date, several genes with mutations linked to familial
forms of PD have been identified, such as α-synuclein,
parkin, PTEN-induced putative kinase 1, DJ-1, tau pro-
tein, and LRRK2. Mutations in all above except LRRK2
have been associated with early-onset or pathologically
atypical forms of PD. Pathogenic mutations in LRRK2
have been recently identified in both autosomal domi-
nant familial PD and sporadic PD [6-11,26], and are thus
far the most important genetic factor for predicting late-
onset familial and sporadic PD [3,27,28]. Apart from the
highest prevalence among PD associated genes, LRRK2
mutations lead to a predominantly late-onset clinical phe-
notype that resembles idiopathic PD [12-14]. LRRK2 has
thus emerged as, perhaps, the most relevant player in the
pathogenesis of PD.
While there is increasing interest in the role of LRRK2 in
the etiology of PD, most studies have focused on genetic
predominance using DNA analysis of living donors. The
paucity of reports on the normal and pathological distri-
bution of LRRK2 protein is likely due in part to the avail-
ability of specific antibodies and the presence of exposed
epitopes of LRRK2 in tissue sections. Instead, an alterna-
tive approach using in situ hybridization has been used to
map mRNA expression of LRRK2 in rodent and human
brains. It has been reported that mRNA of LRRK2 is
expressed in dopamine-receptive (striatum) rather than
dopamine-synthesizing (brainstem) regions in mice, rats
and humans [29,30]. However, no difference was found
between control subjects and PD cases [30]. It is likely that
the mRNA expression levels may not accurately reflect the
accumulation of LRRK2 protein in pathological brains.
Until now, the role of LRRK2 protein in PD pathology
using immunohistochemical detection of LBs with a sin-
gle antibody has thus far proved elusive. Previous studies
have showed that an antiserum against the central region
of LRRK2 do not recognize LBs [25] whereas antisera
directed at the N-terminus [31] and C-terminus [31,32] of
the protein specifically label LBs. The possible reasons for
this discrepancy may be due to the difference in experi-
mental conditions such as tissue processing and antibody
specificity. Analysis of protein localization to LBs, com-
posed of tightly packed filaments, can be inherently diffi-
cult, in particular problems with epitope masking in tissue
sections. In our present study, a battery of specific anti-
bodies directed against different regions of LRRK2 has
been used for detailed analysis of serial tissue sections
from PD and DLB cases. This strategy provides us an
opportunity to overcome obstacles associated with differ-
ential exposure of antigenic sites of LRRK2. Of the four
different antibodies tested, the two antibodies (Ab1 and
Ab4) which strongly label LBs are directed against
epitopes located outside the five folded domains of
LRRK2. The antibody against LRRK21246–1265, Ab2, with
an epitope within the LRRs domain was negative for LB
staining, as previously published [25], as well as negative
for cell bodies and vessels. Indeed, LBs remain unstained
also using an antibody against other folded domains
(LRRK21838–2133), Ab3, yet this antibody still recognized
LRRK2 protein present in the vasculature. We postulate
that LRRK2 sequences outside the folded domains (such
as LRRK2900–1000 and LRRK22500–2527) are highly exposed
in LBs and most other brain structures. However, some
sequences within the folded regions of LRRK2 (such as
LRRK21838–2133) are masked in LBs but not in brain vascu-
lar structures, whereas other sequences (such as
LRRK21246–1265) are masked in LBs as well as other brain
components. It should be noted that all of antibodies
tested have a positive immunoreactivity to LRRK2 on
Western blots. However, as demonstrated in the present
study, their usefulness in recognizing the respective
LRRK2 epitopes in tissue sections differs widely. Our
Specificity of immunostaining for LRRK2Figure 3
Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by 
performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab4 
against LRRK22500–2527 (A) and Ab1 against LRRK2900–100 (C) was blocked using respective peptide antigens (B and D). Adja-
cent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 μm.Page 5 of 9
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Immunocytochemistry of LRRK2 in DLBFigure 4
Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against 
LRRK22500–2527 (A), and Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cor-
tex by Ab4 and with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, 
though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as 
well as by anti-α-synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also 
intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm.
Molecular Neurodegeneration 2006, 1:17 http://www.molecularneurodegeneration.com/content/1/1/17study highlights the importance of vigorous investigation
in immunocytochemical analysis using multiple antibod-
ies against different structural regions to circumvent
epitope masking, especially for a large protein with a com-
plex composition like LRRK2.
In light of the recent in vitro observation that LRRK2 over-
expression leads to protein aggregation in cultured cells
[33], it is particularly intriguing to find an apparent accu-
mulation of LRRK2 in PD brains examined as compared
to control cases. The accumulation of LRRK2 is localized
to LBs, the proteinaceous inclusions, in brain regions
most affected by PD (brainstem) and DLB (cortical area).
Our findings are consistent with a potential gain of func-
tion for LRRK2 in disease pathogenesis, and are in line
with genetic studies [3,27,28] that have found LRRK2
mutations thus far the most frequent cause of autosomal
dominant PD and sporadic PD.
LRRK2 is predicted to contain several functionally impor-
tant domains with multiple scaffold protein modules and
signaling activities, including Ras-related GTPase and
MAPKKK (mitogen-activated protein kinase kinase
kinase) positioned at the top-tier of signal transduction
cascades that regulate diverse arrays of cellular processes
[24,34]. Hence, LRRK2 is likely to contribute to the regu-
latory machinery that helps maintain homeostasis of neu-
ronal functions through its intrinsic enzymatic reactions
such as GTP binding and hydrolysis, and protein phos-
phorylation. Recent reports have confirmed that LRRK2
indeed functions as a kinase and pathogenic mutations
augment its activity in cell culture models [22,23]. Inter-
estingly, two other proteins associated with PD, α-synu-
clein and parkin, are phosphoproteins localized to LBs. It
is well established that α-synuclein is a major component
of LBs [16-18], and selective and extensive phosphoryla-
tion of α-synuclein has been observed in both PD and
DLB [19,20], and in vitro phosphorylation of α-synuclein
has been shown to promote its aggregation [35]. Parkin is
an ubiquitin ligase, also localized to LBs of PD and DLB
[18]. Phosphorylation of parkin has been shown to regu-
late its ubiquitin ligase activity [21]. Importantly, a close
interaction between LRRK2 and parkin has been recently
reported [33]. Our present study has identified LRRK2 as
the first signaling protein that is both genetically associ-
ated with PD and a constituent of its hallmark pathology.
The co-localization of the protein kinase LRRK2 in LBs
may provide a molecular mechanism underlying diver-
gent causes associated with parkinsonism, including aber-
rant protein phosphorylation and subsequent protein
aggregation mediated by α-synuclein and parkin. As the
PD and DLB cases we investigated are sporadic and
patients carrying the common LRRK2 mutations seem to
share a typical late-onset disease presentation [12-14], our
findings suggest a universal role of LRRK2 in etiology and
pathogenesis of parkinsonism. Taken together, we con-
clude that LRRK2 is an essential component of LBs in PD
and DLB. The expression patterns of LRRK2 in normal and
pathological brains we described here will help design
plausible experimental models of PD, and more impor-
tantly strategies toward productive therapeutics.
Conclusion
We have demonstrated that LRRK2 is localized to both
brainstem LBs in idiopathic PD and cortical LBs in DLB,
indicating that LRRK2 is indeed an essential component
of the LBs in these two neurodegenerative diseases. Our
findings suggest that LRRK2 may play an important role in




Tissue samples were obtained from the Case Medical
Center and the National Institute of Child Health and
Human Development (NICHD) Brain and Tissue Bank
for Developmental Disorders. Brain tissue specimens were
obtained postmortem from patients with histopathologi-
cally confirmed PD (n = 6; age range 53–76 years), DLB (n
= 6; age range 68–85 year), and from control patients
without neurological disease (n = 4; age range 42–79 years
for brainstem and n = 5; age range 31–74 for neocortex
samples). Sections of midbrain containing substantia
nigra pars compacta were examined for PD cases, and hip-
pocampus with adjacent cortical tissue was examined for
cases of DLB. Corresponding areas from the control cases
were also examined.
LRRK2 antibodies
Affinity-purified rabbit polyclonal antibodies raised
against different regions of the LRRK2 sequence were used
for this study. These include Ab1 (Cat #NB300-267,
Novus Biologicals, Littleton, CO) raised against LRRK2
residues between 900 and 1000 (LRRK2900–1000); Ab2
(Cat #AP7099b, Abgent, San Diego, CA) raised against
LRRK2 residues between 1246–1265 (LRRK21246–1265);
Ab3 (Cat #ALX-210-928-C100, Alexis Biochemicals, San
Diego, CA) raised against LRRK2 residues between 1838–
2133 (LRRK21838–2133); and Ab4 (Cat #NB300-268,
Novus Biologicals, Littleton, CO) raised against LRRK2
residues 2500–2527 (LRRK22500–2527).
Western blotting
Recombinant LRRK2 was overexpressed in human embry-
onic kidney 293T cell line or human neuroblastoma M17
cell line, following transient transfection with a mamma-
lian expression vector containing human LRRK2 cDNA
(pCMV6-XL4/LRRK2; Origene Techonologies, Rockville,
MD). Transfection was performed using the Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA), andPage 7 of 9
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in phosphate-buffered saline with the Complete protease
inhibitors (Roche Applied Science, Indianapolis, IN))
after 48 h. Brain homogenates prepared from frozen
brainstem samples from cases of Parkinson disease and
age matched controls (10% w/v) were made in a buffer
containing 20 mM Tris, pH 7.5, 150 mM NaCl, 0.5% NP
40, 0.5% Na deoxycolate, and the Complete protease
inhibitors (Roche). The protein concentration was deter-
mined with a DC protein assay kit (Bio-Rad, Hercules,
CA). An equivalent of 100 μg (brain homogenates) or 10
μg (cell lysates) of proteins was used for Western blot
analysis. Cell lysates or brain homogenates were boiled
for 10 minutes in sodium dodecyl sulfate (SDS) sample
buffer (3% SDS; 2 mM EDTA; 10% glycerol; 50 mM Tris-
HCl, pH 6.8). Proteins were separated by SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE, 6% gels), and trans-
ferred to polyvinylidene difluoride membranes. The
membranes were blocked with 10% nonfat milk prepared
in Tris-buffered saline containing 0.1% Tween 20 (TBST)
and then incubated for 16 hours at 4°C with anti-LRRK2
antibodies at appropriate dilutions (Ab1, 1:3,000; Ab2,
1:500; Ab3, 1:5,000; and Ab4, 1:6,000). As an absorption
control, an antibody was incubated with its peptide anti-
gen at the ratio of 1:10 (w/w) for 1 h at room temperature
prior to final dilution. Following incubation with a horse-
radish peroxidase conjugated anti-rabbit secondary anti-
body (Amersham Biosciences, Piscataway, NJ), LRRK2
was visualized by enhanced chemiluminescence (ECL
plus kit; Amersham Biosciences) according to the manu-
facturer's instructions.
Immunocytochemistry
Brain tissue was fixed in formalin and was subsequently
dehydrated through graded ethanol and xylene solutions
and embedded in paraffin. Six-micron thick microtome
sections were prepared and placed on silane-coated slides.
Following hydration, sections were immunostained by
the peroxidase-antiperoxidase procedure using anti-
LRRK2 antibodies at a final dilution of 1:100 to 1:200.
Adjacent sections were also immunostained with an anti-
body to α-synuclein (Chemicon, Temecula, CA) to locate
the Lewy bodies. Purified cortical Lewy bodies were pre-
pared from brain tissue affected by DLB as described [15],
and were subsequently dried onto silane-coated glass
slides for immunostaining of α-synuclein and LRRK2. To
verify the specificity of immunolabeling of LRRK2, pri-
mary antibody was omitted as a negative control. In addi-
tion, adsorption control experiments were performed by
incubating peptides (Novus Biologicals) corresponding to
LRRK2900–1000 and LRRK22500–2527 with corresponding
antibodies on some cases. The diluted primary antibodies
were incubated for 16 hours at 4°C with the peptides (0.2
mg/ml) and used for immunocytochemistry.
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